Skip to content
etf.net

Launched · SEC filings

State Street SPDR S&P Biotech ETF

XBINYSE ArcaSPDRA

$152.05−3.93 (−2.52%)

At close: Nov 2, 2026, 4:00 PM ET

A80/ 100

Rank 1 of 17 in Biotech & Genomics

A80/100Rank 1 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 155.98 to 152.05. Range 152.01 to 156.76. Use the arrow keys to read each point.153.00154.00155.00157.0010 AM12 PM2 PM4 PM
Expense ratio
0.35%
Fund size
$10.8B
1Y total return
+39.0%
Yield · Last 12 months
0.35%
Holdings
164
Avg volume · 30D
8.95M sh
52W range
low $106.30high $169.89
Launched
Filings
SEC EDGAR

The ETF.net XBI Grade

A

Score 80 out of 100

Category
Biotech & Genomics⁠
Rank
1 of 17
Six-pillar profile for XBI. Scores out of 100: Cost 81, Risk 47, Mission 85, Tradability 99, Holdings 88, Durability 89. Strongest: Tradability (99). Weakest: Risk (47). Leans toward Tradability.

Score 80 of 100 falls in the A band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A81 out of 100
    Rank 3 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    A85 out of 100
    Rank 3 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    C47 out of 100
    Rank 10 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    A99 out of 100
    Rank 1 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A88 out of 100
    Rank 2 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    A89 out of 100
    Rank 1 of 17

Our read on XBI

ETF.net Research

In short

ABiotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

  • Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
  • 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
  • Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
  • A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

  • Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comnasdaqomx.com
  • Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
  • One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

XBI Performance

Launched Jan 31, 2006

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

XBI$13,897
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. XBI $13,897. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000$14,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for XBI. Periods over one year show the average yearly return.
PeriodXBI
Year to date+28.0%
1 month−1.1%
3 months+6.1%
1 year+39.0%
3 yearsper year+33.3%
5 yearsper year+4.7%
10 yearsper year+10.9%

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for XBI
YearReturn barXBI
2026 YTD+28.0%
2025+35.9%
2024+1.0%
2023+7.6%

XBI in the news

XBI Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.35%Last 12 months
Payout per share
$0.54Last 12 months
Last payment
$0.14 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Twice a year

Distribution history

2017–2026

One bar per payment. 24 payments from 2017 to 2026 YTD. Mar 17, 2017 $0.02; Jun 16, 2017 $0.11; Sep 15, 2017 $0.04; Dec 15, 2017 $0.04; Mar 16, 2018 $0.06; Jun 15, 2018 $0.06; Sep 21, 2018 $0.07; Dec 21, 2018 $0.01; Sep 20, 2019 $0.0032; Dec 20, 2019 $0.00086; Jun 22, 2020 $0.02; Sep 21, 2020 $0.09; Dec 21, 2020 $0.18; Mar 22, 2021 $0.04; Jun 20, 2023 $0.0026; Dec 18, 2023 $0.01; Jun 24, 2024 $0.11; Sep 23, 2024 $0.02; Dec 23, 2024 $0.0027; Mar 24, 2025 $0.0053; Jun 23, 2025 $0.0073; Sep 22, 2025 $0.03; Dec 22, 2025 $0.41; Jun 22, 2026 $0.14. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Jun 22, 2026Jun 24, 2026$0.14
Dec 22, 2025Dec 24, 2025$0.41
Sep 22, 2025Sep 24, 2025$0.03
Jun 23, 2025Jun 25, 2025$0.0073
Mar 24, 2025Mar 26, 2025$0.0053
Dec 23, 2024Dec 26, 2024$0.0027
Sep 23, 2024Sep 25, 2024$0.02
Jun 24, 2024Jun 26, 2024$0.11
Dec 18, 2023Dec 21, 2023$0.01
Jun 20, 2023Jun 23, 2023$0.0026
Mar 22, 2021Mar 25, 2021$0.04
Dec 21, 2020Dec 24, 2020$0.18

See all 47 payments⁠

$10,000 in XBI 10 years ago paid $270 in dividends.⁠

XBI Risk

Risk pillarC47 out of 100Rank 10 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
24.8%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.11
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−53.2%
Trough May 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.10
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

XBI Cost

Compare XBI and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$3,174

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • XBI 0.35%

    $7,126

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • XBI 0.35%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K051015202530XBI $7,126IBBQ $3,952

Year by year

YearXBIIBBQOverpaying
10$634$347$287
20$2,454$1,351$1,103
30$7,126$3,952$3,174

Other funds in Biotech & Genomics

See others